Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM2 | P08172 | 6/20 | 0.57 |
| ▸ | CHRM1 | P11229 | 6/20 | 0.57 |
| ▸ | CYP2D6 | P10635 | 3/20 | 0.50 |
| ▸ | ADRB2 | P07550 | 2/20 | 0.48 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.46 |
| ▸ | OPRM1 | P35372 | 3/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.45 |
| ▸ | HTR1A | P08908 | 2/20 | 0.45 |
| ▸ | ADRA2A | P08913 | 2/20 | 0.45 |
| ▸ | DRD1 | P21728 | 2/20 | 0.45 |
| ▸ | TBXA2R | P21731 | 2/20 | 0.45 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.45 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.45 |
| ▸ | ADRA1A | P35348 | 2/20 | 0.45 |
| ▸ | DRD3 | P35462 | 2/20 | 0.45 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.45 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.45 |
| ▸ | USP2 | O75604 | 1/20 | 0.45 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22206767 | 1.00 | CHRM2 (0.57) | CHRM2CHRM1CYP2D6ADRB2NPSR1 | |
| SCHEMBL16982012 | 0.85 | CYP2D6 (0.56) | CHRM2CHRM1CYP2D6OPRM1SMN1; SMN2 | |
| SCHEMBL13563401 | 0.82 | MC4R (0.67) | CHRM2CHRM1CYP2D6OPRM1SMN1; SMN2 | |
| SCHEMBL255342 | 0.81 | CYP2D6 (0.68) | CHRM2CHRM1CYP2D6OPRM1SLC6A2 | |
| SCHEMBL5555138 | 0.80 | CYP2D6 (0.43) | CHRM2CHRM1CYP2D6ALDH1A1SLC6A2 | |
| SCHEMBL16935280 | 0.80 | CYP2D6 (0.50) | CHRM2CHRM1CYP2D6OPRM1SLC6A2 | |
| SCHEMBL21075226 | 0.80 | CYP2D6 (0.41) | CHRM2CHRM1CYP2D6ALDH1A1SLC6A2 | |
| SCHEMBL6882628 | 0.80 | CYP2D6 (0.50) | CHRM2CHRM1CYP2D6KCNH2CYP3A4 | |
| SCHEMBL1928612 | 0.80 | CYP2D6 (0.50) | CHRM2CHRM1CYP2D6OPRM1SLC6A2 | |
| SCHEMBL11157003 | 0.80 | ALDH1A1 (0.56) | CHRM2CHRM1CYP2D6OPRM1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240158372-A1 | BISAMIDE SARCOMERE ACTIVATING COMPOUNDS AND USES THEREOF | AMGEN INC. | 2024-05-16 | — | — | US | disclosed |
| US-11780826-B2 | Bisamide sarcomere activating compounds and uses thereof | AMGEN INC. (US) | 2023-10-10 | — | — | US | disclosed |
| US-20220281850-A1 | BISAMIDE SARCOMERE ACTIVATING COMPOUNDS AND USES THEREOF | AMGEN INC. | 2022-09-08 | — | — | US | disclosed |
| US-11299479-B1 | Bisamide sarcomere activating compounds and uses thereof | CYTOKINETICS, INC. (US) | 2022-04-12 | — | — | US | disclosed |
| US-10899746-B2 | Bisamide sarcomere activating compounds and uses thereof | AMGEN INC. (US) | 2021-01-26 | — | — | US | disclosed |
| US-20200223830-A1 | BISAMIDE SARCOMERE ACTIVATING COMPOUNDS AND USES THEREOF | CYTOKINETICS, INC. | 2020-07-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200223830-A1 | BISAMIDE SARCOMERE ACTIVATING COMPOUNDS AND USES THEREOF | TNNI3, TNNT2, TNNC1 | CHRM2 2954/4885CHRM1 3022/4885CYP2D6 4238/4885 |
| US-11780826-B2 | Bisamide sarcomere activating compounds and uses thereof | TNNI3, TNNT2, TNNC1 | CHRM2 2954/4885CHRM1 3022/4885CYP2D6 4238/4885 |
| US-20240158372-A1 | BISAMIDE SARCOMERE ACTIVATING COMPOUNDS AND USES THEREOF | TNNI3, TNNT2, TNNC1 | CHRM2 2954/4885CHRM1 3022/4885CYP2D6 4238/4885 |
| US-20220281850-A1 | BISAMIDE SARCOMERE ACTIVATING COMPOUNDS AND USES THEREOF | TNNI3, TNNT2, TNNC1 | CHRM2 2954/4885CHRM1 3022/4885CYP2D6 4238/4885 |
| US-11299479-B1 | Bisamide sarcomere activating compounds and uses thereof | TNNI3, TNNT2, TNNC1 | CHRM2 2954/4885CHRM1 3022/4885CYP2D6 4238/4885 |
| US-10899746-B2 | Bisamide sarcomere activating compounds and uses thereof | TNNI3, TNNT2, TNNC1 | CHRM2 2954/4885CHRM1 3022/4885CYP2D6 4238/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.